MedTrace Logo

Intravenous Iron Supplement to Prevent Postoperative Delirium After Hip Fracture Surgery

NCT05429749 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 264

Last updated 2022-06-23

No results posted yet for this study

Summary

This is a clinical trial to evaluate the effect of intravenous iron supplement with Ferinject (Ferric Carboxymaltose) in preventing postoperative delirium after hip fracture surgery.

Conditions

  • Hip Fractures

Interventions

DRUG

Ferinject

Intravenous ferinject 1000mg is administered between the admission day and the surgery day.

DRUG

Normal saline

Normal saline 250ml is administered between the admission day and the surgery day.

Sponsors & Collaborators

  • JW Pharmaceutical

    collaborator INDUSTRY

  • Seoul National University Bundang Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-30
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05429749 on ClinicalTrials.gov